Advances in cancer immunotherapy have transformed cancer care and realized
unprecedented responses in many patients. The growing arsenal of novel therapeutics …

Although it has long been known that the immune cell composition has a strong prognostic
and predictive value in colorectal cancer (CRC), scoring systems such as the immunoscore …

Simple Summary Immune Checkpoint Inhibitors (ICIs) have demonstrated clinical efficacy in
Microsatellite Instability High Colorectal Cancer (MSI-H CRC). However, in Microsatellite …

The incidence of rectal cancer is increasing in patients younger than 50 years. Locally
advanced rectal cancer is still treated with neoadjuvant radiation, chemotherapy and …

For locally advanced (T3-4/N+ M0) rectal cancer (LARC), neoadjuvant chemoradiotherapy
(nCRT) followed by total mesorectal excision (TME) is the standard treatment. It was …

PURPOSE No biomarker capable of improving selection and monitoring of patients with
rectal cancer managed by watch-and-wait (W&W) strategy is currently available. Prognostic …

Simple Summary In this review, we present current knowledge of sex hormones in the
process of development of malignant diseases. The impact of sex hormones on immune …

Objectives Partial or total resistance to preoperative chemoradiotherapy occurs in more than
half of locally advanced rectal cancer patients. Several novel or repurposed drugs have …

Radiotherapy is part of the standard of care treatment for a great majority of cancer patients.
As a result of radiation, both tumor cells and the environment around them are affected …

Background Tumor immune cells influence the efficacy of immune-checkpoint inhibitors
(ICIs) and many efforts aim at identifying features of tumor immune microenvironment able to …